Ironwood Pharmaceuticals, Inc. (IRWD) Stock

Ironwood Pharmaceuticals, Inc. (IRWD) is a Healthcare stock trading at $3.54 (as of 2026-06-18), with a market capitalization of $587.67M and a trailing P/E of 5.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ironwood Pharmaceuticals, Inc. is a healthcare company focused on developing and commercializing gastrointestinal products. It markets linaclotide for IBS-C and chronic idiopathic constipation under LINZESS and CONSTELLA, and is also developing IW-3300 for visceral pain conditions and CNP-104 for biliary cholangitis.

Valuation — source: SEC EDGAR (first-party)
Price$3.54
Market Cap$587.67M
P/E Ratio5.7
EV / EBITDA2.8
Price / Book-2.68
Price / Sales1.61
DCF Value (model)$12.14
DCF Upside vs Price242.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$296.15M
Net Margin8.1%
Return on Equity-47.1%
Debt / Equity-0.92
Current Ratio1.41
Revenue Growth (YoY)-15.7%
EPS Growth (YoY)1400.0%
FCF Growth (YoY)22.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.72 (distress)
Valuation vs Sector & Industry
Stock P/E5.7
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-72.7%
vs Industry-66.4%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($98.65M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOThomas A. McCourt
Employees253
CountryUS
IPO Date2010-02-03

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Corvus Pharmaceuticals, Inc. (CRVS)
  • Evommune, Inc. (EVMN)
  • Alto Neuroscience, Inc. (ANRO)
  • Design Therapeutics, Inc. (DSGN)
  • Kyverna Therapeutics, Inc. (KYTX)
  • LB Pharmaceuticals Inc Common Stock (LBRX)
  • Assembly Biosciences, Inc. (ASMB)
  • Prothena Corporation plc (PRTA)
IRWD earnings history · IRWD institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.